medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2025, Number 3

<< Back

Rev Mex Urol 2025; 85 (3)

Acute bladder retention secondary to bladder paraganglioma in an 86-year-old female: case report

Muñoz CRA, Iglesias MG, Iglesias PG, Aguilera AF, Luévano GA

Language: English
References: 15
Page: 1-9
PDF size: 156.77 Kb.


ABSTRACT

Clinical case: an 86-year-old female comes for medical evaluation during an episode of acute urinary retention, upon medical questioning she only reffers previous events of nonspecific chills and malaise; after an urotomography is ordered, an exophytic lesion was identified in the bladder wall. Cystoscopy was performed with resection of the lesion, further inmunohistochemical analysis helped make the diagnosis of sympathetic bladder paraganglioma. Absent catecholamines were found at follow-up.
Relevance: bladder paragangliomas are extraordinarily rare, with an estimated incidence of 0.6-0.8 cases per 100,000 person-years. When located in the abdomen, it affects the organ of Zuckerkandl in 70 % of cases; the bladder is involved in only 10 % of cases of intra-abdominal paraganglioma.
Clinical implications: the cyclic secretion of catecholamines, originated by the neoplastic cells that compose the paraganglioma, causes systemic symptoms related to their activity in other organs. The clinical presentation of sympathetic bladder paragangliomas can be highly insidious, due to the wide range of local and systemic symptoms that can be observed.
Conclusions: due to the local effect of the neoplasm or its catecholaminesecreting activity, the index of suspicion for this type of neoplasm should be high and coupled with a detailed anamnesis to identify the catecholamine-related signs and/or symptoms.


REFERENCES

  1. Young WF. Paragangliomas: clinical overview.Annals of the New York Academy of Sciences. 2006;1073: 21–29. https://doi.org/10.1196/annals.1353.002.

  2. Lee JA, Duh QY. Sporadic Paraganglioma. WorldJournal of Surgery. 2008;32(5): 262. https://doi.org/10.1007/s00268-007-9360-4.

  3. Sunil V N, John K, Nawahirsha S, IyyaduraiR. Micturition syncope: a rare presentationof bladder paraganglioma. BMJ Case Reports.2020;13(9): e235353. https://doi.org/10.1136/bcr-2020-235353.

  4. Neumann HPH, Young WF, Eng C.Pheochromocytoma and Paraganglioma. The NewEngland Journal of Medicine. 2019;381(6): 552–565. https://doi.org/10.1056/NEJMra1806651.

  5. Beard CM, Sheps SG, Kurland LT, Carney JA,Lie JT. Occurrence of pheochromocytoma inRochester, Minnesota, 1950 through 1979. MayoClinic Proceedings. 1983;58(12): 802–804.

  6. Erickson D, Kudva YC, Ebersold MJ,Thompson GB, Grant CS, van Heerden JA, etal. Benign paragangliomas: clinical presentationand treatment outcomes in 236 patients. TheJournal of Clinical Endocrinology and Metabolism.2001;86(11): 5210–5216. https://doi.org/10.1210/jcem.86.11.8034.

  7. Boedeker CC, Neumann HPH, Maier W,Bausch B, Schipper J, Ridder GJ. MalignantHead and Neck Paragangliomas in SDHBMutation Carriers. Otolaryngology–Head andNeck Surgery. 2007;137(1): 126–129. https://doi.org/10.1016/j.otohns.2007.01.015.

  8. Beilan JA, Lawton A, Hajdenberg J, RosserCJ. Pheochromocytoma of the urinary bladder:a systematic review of the contemporaryliterature. BMC Urology. 2013;13(1): 22. https://doi.org/10.1186/1471-2490-13-22.

  9. Manger, William Muir, Ray W Gifford. Clinicaland experimental pheochromocytoma - NationalLibrary of Medicine Institution. Blackwell Science,;1996. https://catalog.nlm.nih.gov/discovery/fulldisplay/alma997903853406676/01NLM_INST:01NLM_INST [Accessed 6th August 2025].

  10. Deng JH, Li HZ, Zhang YS, Liu GH. Functionalparagangliomas of the urinary bladder: areport of 9 cases. Chinese Journal of Cancer.2010;29(8): 729–734. https://doi.org/10.5732/cjc.009.10703.

  11. Garcia-Carbonero R, Matute TeresaF, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I, et al.Multidisciplinary practice guidelines for thediagnosis, genetic counseling and treatmentof pheochromocytomas and paragangliomas.Clinical & Translational Oncology: OfficialPublication of the Federation of Spanish OncologySocieties and of the National Cancer Institute ofMexico. 2021;23(10): 1995–2019. https://doi.org/10.1007/s12094-021-02622-9.

  12. Lenders JWM, Duh QY, Eisenhofer G,Gimenez-Roqueplo AP, Grebe SKG, Murad MH,et al. Pheochromocytoma and paraganglioma:an endocrine society clinical practice guideline.The Journal of Clinical Endocrinology andMetabolism. 2014;99(6): 1915–1942. https://doi.org/10.1210/jc.2014-1498.

  13. Stein PP, Black HR. A simplified diagnosticapproach to pheochromocytoma. A review ofthe literature and report of one institution’sexperience. Medicine. 1991;70(1): 46–66. https://doi.org/10.1097/00005792-199101000-00004.

  14. Bravo EL. Pheochromocytoma: new conceptsand future trends. Kidney International.1991;40(3): 544–556. https://doi.org/10.1038/ki.1991.244.

  15. Shah MH, Goldner WS, Benson AB,Bergsland E, Blaszkowsky LS, Brock P, et al.Neuroendocrine and Adrenal Tumors, Version2.2021, NCCN Clinical Practice Guidelines inOncology. Journal of the National ComprehensiveCancer Network: JNCCN. 2021;19(7): 839–868.https://doi.org/10.6004/jnccn.2021.0032.




2020     |     www.medigraphic.com